CVS CVS HEALTH Corp
Retail-Drug Stores and Proprietary Stores · NYSE · SEC CIK 64803 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.7%
TTM net income YoY2,253.3%
TTM EPS YoY2,165.8%
Revenue 3-yr CAGR6.5%
Net income 3-yr CAGR8.5%
Margins
Gross margin44.2%
Operating margin3.6%
Net margin2.6%
FCF margin3.7%
EBITDA margin4.7%
Returns
ROE14.4%
ROA4.3%
ROIC (approx.)10.8%
Asset turnover1.64x
Leverage & solvency
Liabilities / assets68.7%
Debt / equity0.75x
Current ratio0.85x
Interest coverage4.91x
Cash quality & payout
Operating cash flow / net income1.70x
Accruals ratio-3.0%
Payout ratio31.0%
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $108.40B | $106.10B | $100.43B | $105.69B | $102.87B | $98.92B | $94.59B | $97.71B |
| Cost of revenue | $61.19B | $58.86B | $55.44B | $59.06B | $57.05B | $54.01B | $51.06B | $55.27B |
| Gross profit | $47.21B | $47.23B | $44.98B | $46.63B | $45.83B | $44.91B | $43.53B | $42.44B |
| Operating income | $3.57B | $4.70B | $4.68B | $2.11B | -$3.21B | $2.38B | $3.37B | $2.37B |
| Interest expense | $747.00M | $757.00M | $774.00M | $787.00M | $784.00M | $763.00M | $785.00M | $758.00M |
| Pretax income | $2.85B | $3.98B | $3.94B | $1.35B | -$3.48B | $1.65B | $2.62B | $2.13B |
| Income tax | $678.00M | $982.00M | $981.00M | -$1.57B | $508.00M | $634.00M | $835.00M | $503.00M |
| Net income | $2.17B | $2.98B | $2.94B | $2.94B | -$3.98B | $1.02B | $1.78B | $1.64B |
| EBITDA | $4.70B | $5.83B | $5.79B | $3.26B | -$2.07B | $3.55B | $4.53B | $3.52B |
| EPS (basic) | 1.70 | 2.33 | 2.31 | — | -3.13 | 0.81 | 1.41 | — |
| EPS (diluted) | 1.68 | 2.31 | 2.30 | — | -3.13 | 0.80 | 1.41 | — |
| Dividends declared per share | 0.67 | 0.67 | 0.67 | 0.67 | 0.67 | 0.67 | 0.67 | 0.67 |
| Weighted avg. shares (diluted) | 1.29B | 1.29B | 1.28B | — | 1.27B | 1.27B | 1.26B | — |
| Balance sheet | ||||||||
| Cash & equivalents | $11.74B | $11.33B | $9.54B | $8.45B | $9.35B | $12.03B | $10.35B | $8.88B |
| Short-term investments | $3.15B | $2.63B | $2.26B | $2.15B | $2.13B | $2.39B | $2.58B | $2.41B |
| Receivables | $42.07B | $40.31B | $40.99B | $39.78B | $43.86B | $40.65B | $39.62B | $36.47B |
| Inventory | $18.24B | $17.62B | $17.77B | $19.25B | $18.96B | $17.45B | $17.39B | $18.11B |
| Current assets | $79.39B | $75.35B | $74.82B | $74.71B | $77.11B | $75.65B | $73.19B | $68.64B |
| PP&E, net | $13.32B | $13.17B | $13.04B | $13.08B | $12.84B | $12.82B | $12.86B | $12.99B |
| Goodwill | $85.48B | $85.48B | $85.48B | $85.48B | $85.48B | $91.20B | $91.20B | $91.27B |
| Intangibles | $24.22B | $24.64B | $25.07B | $25.51B | $25.98B | $26.22B | $26.57B | $27.32B |
| Total assets | $258.07B | $253.77B | $252.97B | $253.54B | $255.33B | $258.34B | $255.59B | $253.22B |
| Current liabilities | $93.10B | $87.04B | $86.41B | $88.69B | $92.69B | $94.16B | $88.96B | $84.61B |
| Short-term debt | $3.46B | $1.96B | $2.58B | $4.07B | $1.25B | $3.04B | $1.26B | $2.12B |
| Long-term debt | $57.22B | $59.45B | $60.53B | $60.50B | $60.51B | $57.29B | $59.04B | $60.53B |
| Total debt | $60.68B | $61.41B | $63.11B | $64.57B | $61.76B | $60.33B | $60.30B | $62.65B |
| Total liabilities | $177.39B | $173.87B | $175.34B | $178.16B | $182.22B | $180.79B | $178.47B | $177.49B |
| Shareholders' equity | $80.50B | $79.70B | $77.46B | $75.21B | $72.93B | $77.38B | $76.93B | $75.56B |
| Net debt | $48.94B | $50.08B | $53.57B | $56.12B | $52.40B | $48.30B | $49.95B | $53.76B |
| Shares outstanding | 1.28B | 1.28B | 1.27B | 1.27B | 1.27B | 1.27B | 1.26B | 1.26B |
| Cash flow statement | ||||||||
| Operating cash flow | $4.72B | $6.34B | $4.25B | $3.39B | $796.00M | $1.90B | $4.56B | $1.86B |
| Capital expenditure | $817.00M | $691.00M | $849.00M | $784.00M | $698.00M | $607.00M | $743.00M | $768.00M |
| Free cash flow | $3.91B | $5.65B | $3.40B | $2.61B | $98.00M | $1.29B | $3.81B | $1.09B |
| Investing cash flow | -$2.79B | -$1.88B | -$874.00M | -$2.00B | -$2.09B | -$1.02B | -$762.00M | -$547.00M |
| Financing cash flow | -$1.53B | -$2.69B | -$2.32B | -$2.03B | -$1.38B | $806.00M | -$2.33B | $431.00M |
| Depreciation & amortization | $1.13B | $1.13B | $1.11B | $1.15B | $1.13B | $1.17B | $1.15B | $1.15B |
| Stock-based compensation | $168.00M | $176.00M | $266.00M | $135.00M | $138.00M | $136.00M | $126.00M | $137.00M |
| Dividends paid | $853.00M | $878.00M | $847.00M | $845.00M | $846.00M | $866.00M | $840.00M | $838.00M |
| Share buybacks | — | — | — | $0 | $0 | $0 | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 74 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.